isavuconazole
Selected indexed studies
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. (Lancet, 2016) [PMID:26684607]
- New Perspectives on Antimicrobial Agents: Isavuconazole. (Antimicrob Agents Chemother, 2022) [PMID:35969068]
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. (Lancet Infect Dis, 2016) [PMID:26969258]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. (2019) pubmed
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. (2016) pubmed
- New Perspectives on Antimicrobial Agents: Isavuconazole. (2022) pubmed
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. (2016) pubmed
- Isavuconazole-Animal Data and Clinical Data. (2020) pubmed
- Isavuconazole in chronic pulmonary aspergillosis: What is the evidence? (2025) pubmed
- Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients. (2023) pubmed
- A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections. (2023) pubmed
- A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole. (2024) pubmed
- Use of isavuconazole in mucormycosis: a systematic review. (2025) pubmed